Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2020 Filed Feb 25, 2020 22:20 UTC |
Contreras JaimeSenior Vice President
|
GrantOption (right to buy) · Derivative | 68,578 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002272 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,578 Underlying: Common shares · 68,578 shares Expires 2030-02-20 F7 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:20 UTC |
Contreras JaimeSenior Vice President
|
GrantCommon shares without par value | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002272 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,956 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: On May 10, 2019, the reporting person transferred 22,898 directly owned shares to the Jaime Contreras Marvan 2006 Living Trust. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:22 UTC |
Wainer Andrea FExecutive Vice President
|
GrantOption (right to buy) · Derivative | 82,757 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002274 · edgar.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,757 Underlying: Common shares · 82,757 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,585 on February 21, 2021, 27,586 on February 21, 2022, and 27,586 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:22 UTC |
Wainer Andrea FExecutive Vice President
|
GrantCommon shares without par value | 13,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002274 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,715 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:23 UTC |
Ford Robert BPresident and COO
|
GrantOption (right to buy) · Derivative | 390,896 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002275 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,896 Underlying: Common shares · 390,896 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 130,298 on February 21, 2021, 130,299 on February 21, 2022, and 130,299 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:23 UTC |
Ford Robert BPresident and COO
|
GrantCommon shares without par value | 64,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002275 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,181 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC |
Watkin JaredSenior Vice President
|
GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002276 · edgar.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:24 UTC |
Watkin JaredSenior Vice President
|
GrantCommon shares without par value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002276 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,035 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:25 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantOption (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002277 · edgar.xml · derivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:25 UTC |
MANNING JOSEPH JSenior Vice President
|
GrantCommon shares without par value | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002277 · edgar.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,284 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:26 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantOption (right to buy) · Derivative | 130,298 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002278 · edgar.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,298 Underlying: Common shares · 130,298 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 43,432 on February 21, 2021, 43,433 on February 21, 2022, and 43,433 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:26 UTC |
ALLEN HUBERT LExecutive Vice President
|
GrantCommon shares without par value | 21,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002278 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,384 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:27 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantOption (right to buy) · Derivative | 103,446 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002279 · edgar.xml · derivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,446 Underlying: Common shares · 103,446 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 34,482 on February 21, 2021, 34,482 on February 21, 2022, and 34,482 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:27 UTC |
CAPEK JOHN MExecutive Vice President
|
GrantCommon shares without par value | 16,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002279 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,504 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC |
Moreland Mary KExecutive Vice President
|
GrantOption (right to buy) · Derivative | 87,334 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · derivative · entry 5 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,334 Underlying: Common shares · 87,334 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,111 on February 21, 2021, 29,111 on February 21, 2022, and 29,112 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC |
Moreland Mary KExecutive Vice President
|
GrantCommon shares without par value | 14,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002281 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,311 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
GrantOption (right to buy) · Derivative | 68,578 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002283 · edgar.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,578 Underlying: Common shares · 68,578 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,859 on February 21, 2021, 22,859 on February 21, 2022, and 22,860 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:29 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
GrantCommon shares without par value | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002283 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,812 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:30 UTC |
Karam SammySenior Vice President
|
GrantOption (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002284 · edgar.xml · derivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:31 UTC |
LANE ANDREW HExecutive Vice President
|
GrantOption (right to buy) · Derivative | 126,435 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002285 · edgar.xml · derivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,435 Underlying: Common shares · 126,435 shares Expires 2030-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 42,145 on February 21, 2021, 42,145 on February 21, 2022, and 42,145 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:32 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantOptions (right to buy) · Derivative | 132,182 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002286 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,182 Underlying: Common shares · 132,182 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,060 on February 21, 2021, 44,061 on February 21, 2022, and 44,061 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:32 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
GrantCommon shares without par value | 21,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002286 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,771 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:33 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002287 · edgar.xml · derivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:33 UTC |
PEDERSON MICHAEL JSenior Vice President
|
GrantCommon shares without par value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002287 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,067 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:34 UTC |
Wellisch Alejandro DSenior Vice President
|
GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002288 · edgar.xml · derivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC |
DALE MICHAEL DSenior Vice President
|
GrantOptions (right to buy) · Derivative | 83,818 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002289 · edgar.xml · derivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,818 Underlying: Common shares · 83,818 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,939 on February 21, 2021, 27,939 on February 21, 2022, and 27,940 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC |
DALE MICHAEL DSenior Vice President
|
GrantCommons shares without par value | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002289 · edgar.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,697 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantOption (right to buy) · Derivative | 76,198 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002290 · edgar.xml · derivative · entry 2 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,198 Underlying: Common shares · 76,198 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,399 on February 21, 2021, 25,399 on February 21, 2022, and 25,400 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:35 UTC |
BRYNELSEN CHARLESSenior Vice President
|
GrantCommon shares without par value | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002290 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,961 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:36 UTC |
Earnhardt Lisa DExecutive Vice President
|
GrantOption (right to buy) · Derivative | 114,940 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002291 · edgar.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,940 Underlying: Common shares · 114,940 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,313 on February 21, 2021, 38,313 on February 21, 2022, and 38,314 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:36 UTC |
Earnhardt Lisa DExecutive Vice President
|
GrantCommon shares without par value | 18,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002291 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,801 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:53 UTC |
DALE MICHAEL DSenior Vice President
|
SaleCommon shares without par value | 396 | $88.97 | $35,232.12 |
DisclosureSEC source: 0001179110-20-001896 · edgar.xml · nonDerivative · entry 2 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,947 Read SEC document |
| February 19, 2020 Filed Feb 19, 2020 22:53 UTC |
Moreland Mary KExecutive Vice President
|
SaleCommon shares without par value | 1,019 | $88.97 | $90,660.43 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 3 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,985 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:35 UTC |
Karam SammySenior Vice President
|
Tax withholdingCommon shares without par value | 771 | $89.66 | $69,127.86 |
DisclosureSEC source: 0001179110-20-001884 · edgar.xml · nonDerivative · entry 2 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,705 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:36 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 471 | $89.66 | $42,229.86 |
DisclosureSEC source: 0001179110-20-001887 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,567 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:37 UTC |
Wellisch Alejandro DSenior Vice President
|
Tax withholdingCommon shares without par value | 710 | $89.66 | $63,658.60 |
DisclosureSEC source: 0001179110-20-001891 · edgar.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,958 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:53 UTC |
DALE MICHAEL DSenior Vice President
|
Tax withholdingCommon shares without par value | 951 | $89.66 | $85,266.66 |
DisclosureSEC source: 0001179110-20-001896 · edgar.xml · nonDerivative · entry 1 DALE MICHAEL D · CIK 0001172346 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,343 Read SEC document |
| February 17, 2020 Filed Feb 19, 2020 22:53 UTC |
Moreland Mary KExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,004 | $89.66 | $90,018.64 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,004 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 22:35 UTC |
Karam SammySenior Vice President
|
Tax withholdingCommon shares without par value | 814 | $89.66 | $72,983.24 |
DisclosureSEC source: 0001179110-20-001884 · edgar.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 Read SEC document |
| February 16, 2020 Filed Feb 19, 2020 22:53 UTC |
Moreland Mary KExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,020 | $89.66 | $91,453.20 |
DisclosureSEC source: 0001179110-20-001897 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,008 Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 23:10 UTC |
Wainer Andrea FExecutive Vice President
|
SaleCommon shares without par value | 1,120 | $88.61 | $99,244.54 |
DisclosureSEC source: 0001179110-20-001464 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,140 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.61 to $88.615, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 82,321 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 12 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,642 Underlying: Common shares · 82,321 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 91,121 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 11 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,561 Underlying: Common shares · 91,121 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 213,470 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 10 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 213,470 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 81,709 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 9 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 81,709 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 41,229 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · derivative · entry 8 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,229 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
SaleCommon shares without par value | 509,850 | $89.73 | $45,747,208.98 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 6 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,381 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.87, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 82,321 | $59.94 | $4,934,320.74 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 5 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 91,121 | $44.40 | $4,045,772.40 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 4 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 22:23 UTC |
YOOR BRIAN BExecutive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 213,470 | $38.40 | $8,197,248.00 |
DisclosureSEC source: 0001179110-20-000889 · edgar.xml · nonDerivative · entry 3 YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.